首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1616087

細胞健康篩檢市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Cellular Health Screening Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月02日 | 出版商:

Global Market Insights Inc. | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球細胞健康篩檢市場估值達33億美元，預計2024年至2032年複合年成長率為10.1%。。分子生物學、生物化學和生物資訊學的創新推動了這些進步，從而對細胞健康進行更精確和更全面的評估。下一代定序 (NGS) 和質譜等現代技術極大地改善了與細胞健康相關的生物標記的檢測和定量。這些技術可以對代謝物、蛋白質和遺傳物質進行高解析度分析。

先進的 NGS 平台可以同時分析數千種遺傳變異，為遺傳傾向和細胞對壓力的反應提供有價值的見解。多重測試面板領域在 2023 年佔據市場主導地位，營收達 20 億美元。多重測試面板可以同時分析各種生物標記物，從而更全面地了解個人的細胞健康狀況。這種方法揭示了一系列潛在的健康問題，並描繪了整體福祉的完整圖像。

將各種測試整合到一個面板中可以簡化診斷過程，減少多次預約和樣本採集的需要。這種效率為患者和醫療保健提供者節省了時間，推動了多重測試面板的採用。將多種檢測整合到一個面板中通常可以降低整體測試成本並提高資源利用率。到 2023 年，血液樣本細分市場將佔據 36.5% 的巨大市場佔有率。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	33億美元
預測值	78 億美元
複合年成長率	10.1%

這些廣泛的資料有助於評估整體健康狀況並找出特定問題。血液檢測可以早期發現細胞標記的變化，這對於疾病的早期診斷至關重要。及早識別這些變化可以讓醫療保健提供者更快地進行干預，從而獲得更好的結果和更有效的治療。它們的高靈敏度和特異性能夠實現精確的疾病檢測，支持準確的診斷和有效的健康狀況監測，有助於血液樣本細分市場的成長。

預計到 2032 年，美國細胞健康篩檢市場將達到 27 億美元。根據CDC 的數據，2021 年，25.7% 的成年人患有季節性過敏，7.3% 的成年人患有濕疹，6.2% 的成年人患有食物過敏。一部分的需求。這包括用於分析細胞和分子資料的尖端工具和技術。

產業生態系統分析
產業影響力
- 成長動力
  - 越來越重視預防性健康檢查
  - 細胞健康檢測技術的進步
  - 個人化醫療需求不斷成長
  - 對直接面對消費者的篩檢試劑盒的需求不斷成長
- 產業陷阱與挑戰
  - 報銷範圍有限
  - 缺乏標準化
成長潛力分析
技術景觀
監管環境
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
單一測試板
- 端粒測試
- 氧化壓力測試
- 發炎測試
- 重金屬測試
多重測試板

第 6 章：市場估計與預測：按樣本類型，2021 - 2032

主要趨勢
血液樣本
唾液樣本
血清樣本
尿液樣本

第 7 章：市場估計與預測：按收集地點分類，2021 - 2032 年

主要趨勢
在家裡
在職
醫院
診斷實驗室

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Atomo Diagnostics
Cell Science Systems
Cleveland HeartLab, Inc.
DNA Labs India
Genova Diagnostics
GRAIL, Inc.
Immundiagnostik AG
Laboratory Corporation of America Holdings
OmegaQuant
OPKO Health, Inc.
Quest Diagnostics Inc.
RepeatDx
Segterra, Inc.
SpectraCell Laboratories
Telomere Diagnostics, Inc.

簡介目錄

Product Code: 11173

The Global Cellular Health Screening Market reached a valuation of USD 3.3 billion in 2023 and is projected to grow at a 10.1% CAGR from 2024 to 2032. Advances in cellular health testing technologies have significantly enhanced the ability to monitor and assess cellular function and integrity. Innovations in molecular biology, biochemistry, and bioinformatics have driven these advancements, leading to more precise and comprehensive evaluations of cellular health. Modern technologies like next-generation sequencing (NGS) and mass spectrometry have greatly improved the detection and quantification of biomarkers related to cellular health. These technologies enable high-resolution analysis of metabolites, proteins, and genetic material.

Advanced NGS platforms can analyze thousands of genetic variants simultaneously, offering valuable insights into genetic predispositions and cellular responses to stress. The multi-test panels segment dominated the market in 2023, generating revenue of USD 2 billion. Multi-test panels allow for the simultaneous analysis of various biomarkers, providing a more holistic view of an individual's cellular health. This approach uncovers a spectrum of potential health concerns and paints a complete picture of overall well-being.

Consolidating various tests into a single panel streamlines the diagnostic process, reducing the need for multiple appointments and sample collections. This efficiency saves time for both patients and healthcare providers, driving the adoption of multi-test panels. Integrating multiple assays into one panel often lowers overall testing costs and enhances resource utilization. The blood samples segment held a substantial market share of 36.5% in 2023. Blood samples offer a wealth of information regarding cellular health, encompassing biomarkers, genetic material, and metabolic products.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$3.3 Billion
Forecast Value	$7.8 Billion
CAGR	10.1%

This extensive data aids in evaluating overall health and pinpointing specific concerns. Blood tests can detect changes in cellular markers at an early stage, which is crucial for the early diagnosis of diseases. Early identification of these changes allows healthcare providers to intervene sooner, leading to better outcomes and more effective treatments. Their high sensitivity and specificity enable precise disease detection, supporting accurate diagnosis and effective monitoring of health conditions, thus contributing to the growth of the blood samples segment.

The U.S. market for cellular health screening is projected to reach USD 2.7 billion by 2032. The rising prevalence of seasonal allergies, eczema, and food allergies in the U.S. underscores the need for cellular health screening tests such as inflammation tests. According to the CDC, 25.7% of adults had seasonal allergies, 7.3% had eczema, and 6.2% had food allergies in 2021. This has driven the demand for inflammation testing as part of a preventive health approach in the U.S. The U.S. is home to leading companies and research institutions that drive innovation in cellular health screening technologies. This includes cutting-edge tools and techniques for analyzing cellular and molecular data.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing emphasis on preventive health screening
  - 3.2.1.2 Advances in cellular health testing technologies
  - 3.2.1.3 Growing demand for personalized medicine
  - 3.2.1.4 Rising demand for direct-to-consumer screening kits
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited reimbursement coverage
  - 3.2.2.2 Lack of standardization
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Single test panels
- 5.2.1 Telomere tests
- 5.2.2 Oxidative stress tests
- 5.2.3 Inflammation tests
- 5.2.4 Heavy metals tests
5.3 Multi-test panels

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Blood samples
6.3 Saliva samples
6.4 Serum samples
6.5 Urine samples

Chapter 7 Market Estimates and Forecast, By Collection Site, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 At-home
7.3 In-office
7.4 Hospitals
7.5 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa